Leuven Tolerogenic Protocol for Intestinal Transplantation
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Dec 8, 2014
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Leuven Tolerogenic Protocol for Intestinal Transplantation, is studying a new approach to help patients who are receiving an intestinal transplant. The goal of the trial is to improve the body's acceptance of the transplanted organ by using a special treatment that encourages the immune system to protect the new intestine. This method has been used in the hospital's transplant program since 2000 and is designed to help prevent the body from rejecting the new organ.
If you or a loved one is waiting for an intestinal transplant, you may be eligible to participate in this trial, as it is open to all patients in this situation. However, those who are receiving a living donation are not eligible to join. Participants in the trial will receive the standard care along with this new treatment protocol. The trial is currently recruiting participants, and it aims to create a supportive environment for the body to accept the transplant better. Overall, this research could lead to improved outcomes for future transplant patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients awaiting intestinal transplantation
- Exclusion Criteria:
- • living donation
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials